New drug study for newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study is testing new drugs for people recently diagnosed with multiple myeloma, a blood cancer. It aims to see if the new treatment is safe and effective, and it may offer an additional treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your guardian must sign a consent form to join.
- You must have been recently diagnosed with multiple myeloma, not a relapse.
- Your myeloma must be measurable by blood or urine tests, with certain protein levels.
- You must be in generally good health (able to do daily activities) and follow the study schedule.
- You cannot have other serious illnesses, be pregnant or breastfeeding, or have certain other cancers in the past 3 years.
- You must not have significant nerve damage (peripheral neuropathy) before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
This study tests a combination of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) for people with multiple myeloma who also have moderate liver problems. The goal is to see if this combination is safe and works well for them.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.